Report: J&J under probe over Risperdal
Texas attorney general wants company documents related to sales of the schizophrenia treatment, newspaper says.
NEW YORK (CNNMoney.com) - Johnson & Johnson says it remains under scrutiny from federal and state authorities over the drug manufacturer's sales of its top-selling drug Risperdal, according to a news report.
Johnson & Johnson (up $0.21 to $59.29, Research), a drug and consumer products company based in New Brunswick, N.J., said that in January the Texas attorney general issued a civil-investigative demand to the company's Janssen Pharmaceutica subsidiary, seeking documents related to the sales of the anti-psychotic treatment, according to The Wall Street Journal.
In addition, the company says it was subpoenaed in November 2005 by the U.S. attorney in the Eastern District of Pennsylvania about Risperdal marketing and adverse reactions to the drug, which is used to treat schizophrenia, the Journal reported.
The company was also subpoenaed in 2004 by the Office of the Inspector General of the Office of Personnel Management, seeking documents on Risperdal sales, marketing and clinical trials from 1997 to 2002.
Risperdal sales totaled $3.6 billion in 2005. Johnson & Johnson's 2005 sales totaled $50.5 billion.